HU-210

**HU-210** is a synthetic cannabinoid and a potent agonist at the cannabinoid receptors, first synthesized in 1988 by Raphael Mechoulam's group at the Hebrew University. It exhibits **100 to 800 times greater potency** than Δ9-tetrahydrocannabinol (Δ9-THC, the primary psychoactive ingredient of cannabis) and possesses a much longer duration of action[3][5]. HU-210 acts primarily as a **full agonist** at both **cannabinoid receptor type 1 (CB1)** and **cannabinoid receptor type 2 (CB2)**, with much higher affinity than THC[2][7]. Preclinical studies indicate strong **analgesic, antipyretic, anti-inflammatory, antianxiety, and antidepressant effects**, and also impairments in cognition and spatial memory at high doses[5][6][8]. HU-210 is used primarily in basic research on the endocannabinoid system, and is not approved for medical use. The compound is listed as a Schedule I substance in the US[2].

Other names

(-)-HU-210112830-95-2(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol